E. Yu. Okshina
Research Subjects
E. Yu. Okshina has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- M. M. Luk'YAnov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
31 shared publications - Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
28 shared publications - Sergey Yu. Martsevich
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
27 shared publications - N. A. Dmitrieva
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
25 shared publications - Natalia P. Kutishenko
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
25 shared publications - V. P. Voronina
National Medical Research Center for Therapy and Preventive Medicine
25 shared publications
Latest Publications
- Open Access
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12) , 4690
Сomorbidities, risk factors and causes of death in patients with myocardial infarction of different prescription, based on follow-up after hospitalization at a multidisciplinary center
Aim. To analyze multimorbidity, risk factors for death, its incidence, and causes, based on long-term follow-up after hospitalization at a multidisciplinary center for acute myocardial infarction (MI) or other pathologies associated with old myocardial infarction. Material and methods. The SOFIT registry included 855 patients treated for acute MI and 1341 patients treated for other pathologies associated with old MI (age (M±SD) — 64,1±12,1 and 65,8±10,9 years; men — 65,6% and 69,7%). The median [interquartile range] follow-up duration was 2,6 [2,2; 2,9] years. Results. Multimorbidity in the comparison groups was recorded in 97,1 and 94,8% of cases (p=0,01), while cardiovascular multimorbidity — in 95,4 and 86,1% (pConclusion. Patients after myocardial infarction (MI), regardless of its duration, are characterized by a high death risk due to comorbid pathology, which is significantly reduced by appropriate combination cardiovascular pharmacotherapy.
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12) , 4690
Open AccessСomorbidities, risk factors and causes of death in patients with myocardial infarction of different prescription, based on follow-up after hospitalization at a multidisciplinary center
Aim. To analyze multimorbidity, risk factors for death, its incidence, and causes, based on long-term follow-up after hospitalization at a multidisciplinary center for acute myocardial infarction (MI) or other pathologies associated with old myocardial infarction. Material and methods. The SOFIT registry included 855 patients treated for acute MI and 1341 patients treated for other pathologies associated with old MI (age (M±SD) — 64,1±12,1 and 65,8±10,9 years; men — 65,6% and 69,7%). The median [interquartile range] follow-up duration was 2,6 [2,2; 2,9] years. Results. Multimorbidity in the comparison groups was recorded in 97,1 and 94,8% of cases (p=0,01), while cardiovascular multimorbidity — in 95,4 and 86,1% (pConclusion. Patients after myocardial infarction (MI), regardless of its duration, are characterized by a high death risk due to comorbid pathology, which is significantly reduced by appropriate combination cardiovascular pharmacotherapy.
- Open Access
- 22 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (6) , 563-570
Patients with combination of coronary artery disease and chronic kidney disease in clinical practice: comorbidities and cardiovascular pharmacotherapy
Aim. To define the proportion of comorbid chronic kidney disease (CKD) in the cohort of patients with coronary artery disease (CAD) and to estimate the incidence of comorbidities and required cardiovascular pharmacotherapy on a basis of united data from several medical registries. Material and methods. We have analyzed the united data from 11 registries of patients with cardiovascular diseases (CVD) created in 6 regions of Russia under the supervision of the National Medical Research Center for Therapy and Preventive Medicine. There are 13089 patients with IHD in those registries including 1419 (10.8%) with CAD and CKD combination (36.6% men, age 73.1±9.4 years), 10649 (81.4%) patients with CAD without CKD (48.9% men, age 68.2±9.4 years). There are 1021 (7.8%) patients without convincing data for presence or absence of CKD. The CAD criterion was registration of this diagnosis in medical documents. The CKD criterion was registration of this diagnosis in medical documents and/or low glomerular filtration rate (2 ) revealed at least twice with an interval not less than 3 months. Results. The incidence of cardiovascular multimorbidity in patients with CAD and CKD combination was bigger than in patients with CAD without CKD (96.0% vs 90.3%; рConclusion. The pooled data of 11 registries of patients with CAD demonstrated 10.8% rate of the combination with CKD. The incidence of cardiovascular multimorbidity, average number of CVD in patients with CAD and CKD combination were significantly bigger in cases of diabetes and history of MI and ACVA. The incidence of required cardiovascular pharmacotherapy accordingly the main indications in patients with CAD and CKD combination was insufficient (58%) and was some bigger in subgroups with history of MI and ACVA but lower in presence of diabetes (55.9%). In patients with CAD and CKD combination, especially against the background of diabetes mellitus, it is necessary to increase the frequency of prognostically significant cardiovascular pharmacotherapy in clinical practice.
- 22 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (6) , 563-570
Open AccessPatients with combination of coronary artery disease and chronic kidney disease in clinical practice: comorbidities and cardiovascular pharmacotherapy
Aim. To define the proportion of comorbid chronic kidney disease (CKD) in the cohort of patients with coronary artery disease (CAD) and to estimate the incidence of comorbidities and required cardiovascular pharmacotherapy on a basis of united data from several medical registries. Material and methods. We have analyzed the united data from 11 registries of patients with cardiovascular diseases (CVD) created in 6 regions of Russia under the supervision of the National Medical Research Center for Therapy and Preventive Medicine. There are 13089 patients with IHD in those registries including 1419 (10.8%) with CAD and CKD combination (36.6% men, age 73.1±9.4 years), 10649 (81.4%) patients with CAD without CKD (48.9% men, age 68.2±9.4 years). There are 1021 (7.8%) patients without convincing data for presence or absence of CKD. The CAD criterion was registration of this diagnosis in medical documents. The CKD criterion was registration of this diagnosis in medical documents and/or low glomerular filtration rate (2 ) revealed at least twice with an interval not less than 3 months. Results. The incidence of cardiovascular multimorbidity in patients with CAD and CKD combination was bigger than in patients with CAD without CKD (96.0% vs 90.3%; рConclusion. The pooled data of 11 registries of patients with CAD demonstrated 10.8% rate of the combination with CKD. The incidence of cardiovascular multimorbidity, average number of CVD in patients with CAD and CKD combination were significantly bigger in cases of diabetes and history of MI and ACVA. The incidence of required cardiovascular pharmacotherapy accordingly the main indications in patients with CAD and CKD combination was insufficient (58%) and was some bigger in subgroups with history of MI and ACVA but lower in presence of diabetes (55.9%). In patients with CAD and CKD combination, especially against the background of diabetes mellitus, it is necessary to increase the frequency of prognostically significant cardiovascular pharmacotherapy in clinical practice.
- 1 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (11) , 36-44
Multimorbidity, risk factors and causes of death in patients with cardiovascular diseases during long-term posthospital monitoring
Objective. To conduct a comparative analysis of the frequency, causes, and risk factors of death in patients with cardiovascular diseases according to long-term follow-up after hospitalization in various departments of a multifaceted hospital. Materials and methods. Multimorbidity, history of coronavirus infection (COVID-19), frequency, causes, and risk factors of death during the follow-up period of 2.6 [2.3; 2.8] years were assessed in 13/551 patients with cardiovascular diseases (CVD) after discharge from the various departments in the proSpective registry Of a multiFaceted medIcal cenTer (SOFIT). Results. Two or more CVDs and non-cardiac diseases were reported in 81.4% of cases, cardiovascular multimorbidity in 47.5%, non-cardiac multimorbidity in 52.4%, and their combination in 17.9% of patients. 15.5% of patients died. On average, the highest mortality per year was reported in patients discharged from the emergency cardiology department (9.0%), the lowest from the cardiology department (4.4%), and from the departments of therapeutic and other profiles — 5.6 and 6.6%, respectively. The proportion of deaths from cardiovascular causes among deceased patients with CVD was 35.8%. The mortality risk was associated with age and male sex, increased by 1.2—1.7 times in the presence of a history of myocardial infarction, cerebrovascular accident, diabetes mellitus, chronic obstructive pulmonary disease, or inpatient treatment for COVID-19. The COVID-19-related mortality risk increased with age, and was several times lower in patients with a history of previous outpatient and inpatient treatment for this disease (8.2 and 4.9 times). Conclusion. In patients with cardiovascular diseases, monitored in the long-term follow-up after treatment in a multifaceted hospital, multimorbidity was reported in 81.4% of cases, both cardiovascular and non-cardiac multimorbidity in about 50% of cases, and their combination in 17.9% of patients. 15.5% of patients died. The mean proportion of deaths per year was the highest among those discharged from the emergency cardiology department (9.0%), and the lowest from the cardiology department (4.4%). Cardiovascular causes of death were reported in a minority of deceased cardiovascular patients due to non-cardiac comorbidity. The risk of death from all and cardiovascular causes was associated with age, male sex, previous myocardial infarction, cerebrovascular accident, diabetes mellitus, chronic obstructive pulmonary disease, and a history of inpatient treatment for COVID-19. In patients with cardiovascular diseases, the higher risk of COVID-19-related mortality associated with age was several times lower in those with a history of the disease.
- 1 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (11) , 36-44
Multimorbidity, risk factors and causes of death in patients with cardiovascular diseases during long-term posthospital monitoring
Objective. To conduct a comparative analysis of the frequency, causes, and risk factors of death in patients with cardiovascular diseases according to long-term follow-up after hospitalization in various departments of a multifaceted hospital. Materials and methods. Multimorbidity, history of coronavirus infection (COVID-19), frequency, causes, and risk factors of death during the follow-up period of 2.6 [2.3; 2.8] years were assessed in 13/551 patients with cardiovascular diseases (CVD) after discharge from the various departments in the proSpective registry Of a multiFaceted medIcal cenTer (SOFIT). Results. Two or more CVDs and non-cardiac diseases were reported in 81.4% of cases, cardiovascular multimorbidity in 47.5%, non-cardiac multimorbidity in 52.4%, and their combination in 17.9% of patients. 15.5% of patients died. On average, the highest mortality per year was reported in patients discharged from the emergency cardiology department (9.0%), the lowest from the cardiology department (4.4%), and from the departments of therapeutic and other profiles — 5.6 and 6.6%, respectively. The proportion of deaths from cardiovascular causes among deceased patients with CVD was 35.8%. The mortality risk was associated with age and male sex, increased by 1.2—1.7 times in the presence of a history of myocardial infarction, cerebrovascular accident, diabetes mellitus, chronic obstructive pulmonary disease, or inpatient treatment for COVID-19. The COVID-19-related mortality risk increased with age, and was several times lower in patients with a history of previous outpatient and inpatient treatment for this disease (8.2 and 4.9 times). Conclusion. In patients with cardiovascular diseases, monitored in the long-term follow-up after treatment in a multifaceted hospital, multimorbidity was reported in 81.4% of cases, both cardiovascular and non-cardiac multimorbidity in about 50% of cases, and their combination in 17.9% of patients. 15.5% of patients died. The mean proportion of deaths per year was the highest among those discharged from the emergency cardiology department (9.0%), and the lowest from the cardiology department (4.4%). Cardiovascular causes of death were reported in a minority of deceased cardiovascular patients due to non-cardiac comorbidity. The risk of death from all and cardiovascular causes was associated with age, male sex, previous myocardial infarction, cerebrovascular accident, diabetes mellitus, chronic obstructive pulmonary disease, and a history of inpatient treatment for COVID-19. In patients with cardiovascular diseases, the higher risk of COVID-19-related mortality associated with age was several times lower in those with a history of the disease.
- Open Access
- 29 December 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (6) , 637-644
Medical treatment of cardiovascular diseases in patients after hospitalization for COVID-19 (three-year follow-up data in the TARGET-VIP registry)
Aim. To evaluate the quality of drug treatment of patients with cardiovascular diseases (CVD) at the remote stage of follow-up after hospitalization for new coronavirus infection (COronaVIrus Disease 2019, COVID-19) within the framework of the prospective TARGET-VIP registry.Material and methods. 1,130 people were included in the registry. The 473 (54.8%) patients with CVD were selected of the 863 patients discharged from the hospital with a diagnosis of COVID-19.Results. The frequency of proper prescriptions of medicines upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4% (pConclusion. The quality of CVD therapy was insufficient at all stages of long-term follow-up: the frequency of proper prescriptions upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4%. A clear trend was revealed in a decrease in the frequency of taking all drugs, while for some groups of drugs this decrease reached statistically significant differences. The quality of cardiovascular pharmacotherapy was higher with the appearance / development of new CVD in comparison with the group of stable patients with CVD, there was no significant improvement in the quality of therapy for previously observed CVD.
- 29 December 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (6) , 637-644
Open AccessMedical treatment of cardiovascular diseases in patients after hospitalization for COVID-19 (three-year follow-up data in the TARGET-VIP registry)
Aim. To evaluate the quality of drug treatment of patients with cardiovascular diseases (CVD) at the remote stage of follow-up after hospitalization for new coronavirus infection (COronaVIrus Disease 2019, COVID-19) within the framework of the prospective TARGET-VIP registry.Material and methods. 1,130 people were included in the registry. The 473 (54.8%) patients with CVD were selected of the 863 patients discharged from the hospital with a diagnosis of COVID-19.Results. The frequency of proper prescriptions of medicines upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4% (pConclusion. The quality of CVD therapy was insufficient at all stages of long-term follow-up: the frequency of proper prescriptions upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4%. A clear trend was revealed in a decrease in the frequency of taking all drugs, while for some groups of drugs this decrease reached statistically significant differences. The quality of cardiovascular pharmacotherapy was higher with the appearance / development of new CVD in comparison with the group of stable patients with CVD, there was no significant improvement in the quality of therapy for previously observed CVD.
- Open Access
- 24 October 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (9) , 4109
Typical profile of a patient with atrial fibrillation in the Russian population based on medical registries. A systematic review
Aim. To compare clinical and anamnestic characteristics of patients with atrial fibrillation (AF) included in three large international studies assessing the efficacy and safety of therapy with direct oral anticoagulants, with the profile of a typical Russian patient with AF in clinical practice, established by medical registries in the Russian Federation (RF).Material and methods. A systematic review of scientific publications was conducted. The search was conducted in the E-library and Google Scholar databases. Publications from 8 registries of patients with AF, conducted in the Russian Federation from 2012 to 2023, were found, which present the clinical and anamnestic characteristics of patients. All studies included in the analysis meet the generally accepted requirements for medical registries. The systematic review protocol was previously recorded in the PROSPERO electronic database (CRD42024512425).Results. A Russian patient with AF is a patient with a large number of cardiovascular pathologies and a high risk of thromboembolic events. According to the analysis, Russian patient with AF has an average age of ~70 years. Most patients have a diagnosis of hypertension, heart failure, while from one third to half of patients have a diagnosis of chronic kidney disease. From 20 to 30% of patients have a history of myocardial infarction and every fifth patient has type 2 diabetes.Conclusion. In all countries around the world, including the Russian Federation, for many years, medical registries have been one of the main sources of information on the characteristics of patients with AF and the disease course. They can supplement the available data from randomized clinical trials with real-world data. Comparison of clinical and anamnestic characteristics of patients in randomized clinical trials of direct oral anticoagulants with characteristics of patients in the Russian registries shows that patients included in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial) were most similar to Russian patients with AF.
- 24 October 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (9) , 4109
Open AccessTypical profile of a patient with atrial fibrillation in the Russian population based on medical registries. A systematic review
Aim. To compare clinical and anamnestic characteristics of patients with atrial fibrillation (AF) included in three large international studies assessing the efficacy and safety of therapy with direct oral anticoagulants, with the profile of a typical Russian patient with AF in clinical practice, established by medical registries in the Russian Federation (RF).Material and methods. A systematic review of scientific publications was conducted. The search was conducted in the E-library and Google Scholar databases. Publications from 8 registries of patients with AF, conducted in the Russian Federation from 2012 to 2023, were found, which present the clinical and anamnestic characteristics of patients. All studies included in the analysis meet the generally accepted requirements for medical registries. The systematic review protocol was previously recorded in the PROSPERO electronic database (CRD42024512425).Results. A Russian patient with AF is a patient with a large number of cardiovascular pathologies and a high risk of thromboembolic events. According to the analysis, Russian patient with AF has an average age of ~70 years. Most patients have a diagnosis of hypertension, heart failure, while from one third to half of patients have a diagnosis of chronic kidney disease. From 20 to 30% of patients have a history of myocardial infarction and every fifth patient has type 2 diabetes.Conclusion. In all countries around the world, including the Russian Federation, for many years, medical registries have been one of the main sources of information on the characteristics of patients with AF and the disease course. They can supplement the available data from randomized clinical trials with real-world data. Comparison of clinical and anamnestic characteristics of patients in randomized clinical trials of direct oral anticoagulants with characteristics of patients in the Russian registries shows that patients included in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial) were most similar to Russian patients with AF.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (12)
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data)
Objective. To assess the distant outcomes during three-year post-hospital follow-up of patients after in-patient care for COronaVIrus Disease 2019 (COVID-19) in a prospective registry. Materials and methods. Outcomes for 3.2±0.7 years of follow-up after hospitalization for COVID-19 were analyzed in 836 patients (age 60.2±14.7 years, 51.2% were males). Cases of death, development of non-fatal myocardial infarction (MI) and non-fatal cerebral stroke (CS), hospitalizations, recurrent COVID-19 were evaluated. Results. During the follow-up period, 63 (7.5%) patients died, 8 (0.96%) cases of MI were registered and 9 (1.1%) — CS, 270 (32.3%) patients were hospitalized, 174 (20.8%) re-suffered COVID-19. Patients with cardiovascular multimorbidity had higher mortality (by a factor of 7), incidence of non-fatal MI and CS, hospitalization than in persons without cardiovascular diseases (CVDs). Male sex is associated with risk of death: HR=2.077, p=0.007. Factors of age, intensive care unit stay during reference hospitalization are associated (p<0.005) not only with the risk of death from all causes (hazard ratio (HR)=1.065 and HR=4.2, respectively), but also with the risk of composite endpoint development (death, non-fatal MI and CS, revascularization procedures): odds ratio (OR)=1.033 and OR=1.85. Hospitalization is associated with older age (OR)=1.027; p<0.001), presence of CVDs (OR=1.66; p=0.01) and chronic non-cardiac diseases (OR=1.51; p=0.013). Risk of developing new CVDs and non-cardiac diseases is associated with older age (OR=1.02; p=0.03). Risk of COVID-19 recurrent cases is higher in presence of CVDs (HR=1.62; p=0.011), lower in persons vaccinated against SARS-CoV-2 (HR=0.55; p<0.001). Higher acute upper respiratory infections morbidity is associated (p<0.001) with younger age and lack of non-cardiac multimorbidity. Conclusion. The proportion of dead amounted to 7.5% for 3 years of post-hospital follow-up of patients for COVID-19, hospitalizations and COVID-19 recurrent cases were the most frequent events. Mortality was 7 times higher in the group with cardiovascular multimorbidity than in persons without cardiovascular diseases. Factors associated with the fatal outcome development were the following: age, cardiovascular and non-cardiac multimorbidity, treatment in the intensive care unit during reference hospitalization. Risk of re-hospitalization for any cause is associated with older age, presence of cardiovascular diseases and non-cardiac diseases. Risk of COVID-19 recurrent cases was 1.5 times higher in presence of cardiovascular diseases, but almost 2 times lower in vaccinated against SARS-CoV-2 subjects in the post-COVID period.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (12)
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data)
Objective. To assess the distant outcomes during three-year post-hospital follow-up of patients after in-patient care for COronaVIrus Disease 2019 (COVID-19) in a prospective registry. Materials and methods. Outcomes for 3.2±0.7 years of follow-up after hospitalization for COVID-19 were analyzed in 836 patients (age 60.2±14.7 years, 51.2% were males). Cases of death, development of non-fatal myocardial infarction (MI) and non-fatal cerebral stroke (CS), hospitalizations, recurrent COVID-19 were evaluated. Results. During the follow-up period, 63 (7.5%) patients died, 8 (0.96%) cases of MI were registered and 9 (1.1%) — CS, 270 (32.3%) patients were hospitalized, 174 (20.8%) re-suffered COVID-19. Patients with cardiovascular multimorbidity had higher mortality (by a factor of 7), incidence of non-fatal MI and CS, hospitalization than in persons without cardiovascular diseases (CVDs). Male sex is associated with risk of death: HR=2.077, p=0.007. Factors of age, intensive care unit stay during reference hospitalization are associated (p<0.005) not only with the risk of death from all causes (hazard ratio (HR)=1.065 and HR=4.2, respectively), but also with the risk of composite endpoint development (death, non-fatal MI and CS, revascularization procedures): odds ratio (OR)=1.033 and OR=1.85. Hospitalization is associated with older age (OR)=1.027; p<0.001), presence of CVDs (OR=1.66; p=0.01) and chronic non-cardiac diseases (OR=1.51; p=0.013). Risk of developing new CVDs and non-cardiac diseases is associated with older age (OR=1.02; p=0.03). Risk of COVID-19 recurrent cases is higher in presence of CVDs (HR=1.62; p=0.011), lower in persons vaccinated against SARS-CoV-2 (HR=0.55; p<0.001). Higher acute upper respiratory infections morbidity is associated (p<0.001) with younger age and lack of non-cardiac multimorbidity. Conclusion. The proportion of dead amounted to 7.5% for 3 years of post-hospital follow-up of patients for COVID-19, hospitalizations and COVID-19 recurrent cases were the most frequent events. Mortality was 7 times higher in the group with cardiovascular multimorbidity than in persons without cardiovascular diseases. Factors associated with the fatal outcome development were the following: age, cardiovascular and non-cardiac multimorbidity, treatment in the intensive care unit during reference hospitalization. Risk of re-hospitalization for any cause is associated with older age, presence of cardiovascular diseases and non-cardiac diseases. Risk of COVID-19 recurrent cases was 1.5 times higher in presence of cardiovascular diseases, but almost 2 times lower in vaccinated against SARS-CoV-2 subjects in the post-COVID period.
- 28 December 2023
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 26 (12)
Long-term outcomes in patients with cardiovascular multimorbidity suffered from COVID-19: two-year observation
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить отдаленные исходы и статус у пациентов с кардиоваскулярной мультиморбидностью (КВММ) в сравнении с пациентами без сердечно-сосудистых заболеваний (ССЗ) через 2 года после госпитализации по поводу COVID-19. МАТЕРИАЛ И МЕТОДЫ В регистре ТАРГЕТ-ВИП у пациентов с подтвержденным в стационаре диагнозом COVID-19 КВММ была определена как наличие двух и более из следующих ССЗ: артериальная гипертония (АГ), ишемическая болезнь сердца (ИБС), хроническая сердечная недостаточность (ХСН), фибрилляция предсердий (ФП). Группу с КВММ составили 163 человека (возраст 73,7±9,6 года; 53,9% мужчин), а группу без ССЗ — 382 человека (возраст 49,4±12,4 года; 58,4% мужчин). Через 28,1±4,6 мес из репрезентативной выборки выживших пациентов опрошены и обследованы 27 пациентов с КВММ (возраст 73,2±9,9 года; 44,4% мужчин) и 144 пациента без ССЗ (возраст 52,2±10,8 года; 52,1% мужчин). Исходная информация получена из историй болезни, а при наблюдении — по результатам телефонных опросов пациентов за период 24 мес, амбулаторных визитов и из электронных баз данных. РЕЗУЛЬТАТЫ У пациентов с КВММ по сравнению с группой без ССЗ были выше смертность от всех причин (19,0% и 3,1%; p=0,001), частота случаев госпитализации (49,7% и 16,5%; p=0,001), однако частота случаев острой респираторной вирусной инфекции (ОРВИ) / гриппа была ниже (44,8% и 64,7%; p1/ФЖЕЛ (p=0,0002). По данным пульсоксиметрии, показатель SpO2 менее 95% перед спирометрией выявлялся чаще у пациентов с КВММ (14,8% и 4,2%; p=0,03), а за все время проведения спирометрии — в 3 раза чаще (25,9% по сравнению с 8,4%; p=0,008). У больных с КВММ частота выявления патологических изменений в легких при мультиспиральной компьютерной томографии (МСКТ) была в 2,2 раза выше (57,7% по сравнению с 26,5%; p=0,002). ЗАКЛЮЧЕНИЕ У перенесших COVID-19 пациентов с КВММ по сравнению с пациентами без ССЗ за 24 мес наблюдения были выше следующие показатели: доля случаев смерти от всех причин (в 6,1 раза), частота случаев нефатальных инфаркта миокарда и мозгового инсульта, частота случаев госпитализации (в 3 раза), но меньше частота ОРВИ/гриппа (в 1,4 раза). Пациенты без ССЗ были более привержены вакцинации против SARS-CoV-2. У пациентов с КВММ, по результатам спирометрии и мониторирования пульсоксиметрии, чаще встречалось снижение показателей функции внешнего дыхания и SpO2. Частота выявления патологии легких при МСКТ была в 2,2 раза выше у пациентов с КВММ.
- 28 December 2023
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 26 (12)
Long-term outcomes in patients with cardiovascular multimorbidity suffered from COVID-19: two-year observation
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить отдаленные исходы и статус у пациентов с кардиоваскулярной мультиморбидностью (КВММ) в сравнении с пациентами без сердечно-сосудистых заболеваний (ССЗ) через 2 года после госпитализации по поводу COVID-19. МАТЕРИАЛ И МЕТОДЫ В регистре ТАРГЕТ-ВИП у пациентов с подтвержденным в стационаре диагнозом COVID-19 КВММ была определена как наличие двух и более из следующих ССЗ: артериальная гипертония (АГ), ишемическая болезнь сердца (ИБС), хроническая сердечная недостаточность (ХСН), фибрилляция предсердий (ФП). Группу с КВММ составили 163 человека (возраст 73,7±9,6 года; 53,9% мужчин), а группу без ССЗ — 382 человека (возраст 49,4±12,4 года; 58,4% мужчин). Через 28,1±4,6 мес из репрезентативной выборки выживших пациентов опрошены и обследованы 27 пациентов с КВММ (возраст 73,2±9,9 года; 44,4% мужчин) и 144 пациента без ССЗ (возраст 52,2±10,8 года; 52,1% мужчин). Исходная информация получена из историй болезни, а при наблюдении — по результатам телефонных опросов пациентов за период 24 мес, амбулаторных визитов и из электронных баз данных. РЕЗУЛЬТАТЫ У пациентов с КВММ по сравнению с группой без ССЗ были выше смертность от всех причин (19,0% и 3,1%; p=0,001), частота случаев госпитализации (49,7% и 16,5%; p=0,001), однако частота случаев острой респираторной вирусной инфекции (ОРВИ) / гриппа была ниже (44,8% и 64,7%; p1/ФЖЕЛ (p=0,0002). По данным пульсоксиметрии, показатель SpO2 менее 95% перед спирометрией выявлялся чаще у пациентов с КВММ (14,8% и 4,2%; p=0,03), а за все время проведения спирометрии — в 3 раза чаще (25,9% по сравнению с 8,4%; p=0,008). У больных с КВММ частота выявления патологических изменений в легких при мультиспиральной компьютерной томографии (МСКТ) была в 2,2 раза выше (57,7% по сравнению с 26,5%; p=0,002). ЗАКЛЮЧЕНИЕ У перенесших COVID-19 пациентов с КВММ по сравнению с пациентами без ССЗ за 24 мес наблюдения были выше следующие показатели: доля случаев смерти от всех причин (в 6,1 раза), частота случаев нефатальных инфаркта миокарда и мозгового инсульта, частота случаев госпитализации (в 3 раза), но меньше частота ОРВИ/гриппа (в 1,4 раза). Пациенты без ССЗ были более привержены вакцинации против SARS-CoV-2. У пациентов с КВММ, по результатам спирометрии и мониторирования пульсоксиметрии, чаще встречалось снижение показателей функции внешнего дыхания и SpO2. Частота выявления патологии легких при МСКТ была в 2,2 раза выше у пациентов с КВММ.
- 5 December 2023
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 26 (11) , 64
Comorbidity and long-term survival of patients suffered from acute cerebrovascular accident based on the REGION-M registry
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить влияние коморбидных заболеваний на отдаленную выживаемость больных, перенесших острое нарушение мозгового кровообращения (ОНМК). МАТЕРИАЛ И МЕТОДЫ В амбулаторную часть регистра РЕГИОН-М включены 684 пациента, прикрепленных к ГБУЗ города Москвы «Городская поликлиника №64 Департамента здравоохранения города Москвы», выписанных из ГБУЗ города Москвы «Городская клиническая больница им. Ф.И. Иноземцева Департамента здравоохранения города Москвы» в период с 01.01.12 по 30.04.17 с подтвержденным диагнозом ОНМК (инсульт или транзиторная ишемическая атака). Амбулаторный этап наблюдения с 2017 по 2022 г. составил 5,5 (2,4—7,0) года. В качестве конечной точки выбрана «смерть от всех причин». РЕЗУЛЬТАТЫ В однофакторном анализе негативное влияние на прогноз имели наличие ишемической болезни сердца (p<0,0001), перенесенный инфаркт миокарда (p<0,0001), наличие сахарного диабета (p<0,05) и ожирения (p<0,01). В многофакторном анализе, включающем, помимо коморбидных заболеваний, пол и возраст, статистическую значимость сохранил только перенесенный инфаркт миокарда в анамнезе (ОР смерти 1,009 (95%ДИ 1,004—1,014, p<0,001). ЗАКЛЮЧЕНИЕ У пациентов, перенесших ОНМК, отдаленную выживаемость ухудшало только наличие инфаркта миокарда в анамнезе.
- 5 December 2023
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 26 (11) , 64
Comorbidity and long-term survival of patients suffered from acute cerebrovascular accident based on the REGION-M registry
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить влияние коморбидных заболеваний на отдаленную выживаемость больных, перенесших острое нарушение мозгового кровообращения (ОНМК). МАТЕРИАЛ И МЕТОДЫ В амбулаторную часть регистра РЕГИОН-М включены 684 пациента, прикрепленных к ГБУЗ города Москвы «Городская поликлиника №64 Департамента здравоохранения города Москвы», выписанных из ГБУЗ города Москвы «Городская клиническая больница им. Ф.И. Иноземцева Департамента здравоохранения города Москвы» в период с 01.01.12 по 30.04.17 с подтвержденным диагнозом ОНМК (инсульт или транзиторная ишемическая атака). Амбулаторный этап наблюдения с 2017 по 2022 г. составил 5,5 (2,4—7,0) года. В качестве конечной точки выбрана «смерть от всех причин». РЕЗУЛЬТАТЫ В однофакторном анализе негативное влияние на прогноз имели наличие ишемической болезни сердца (p<0,0001), перенесенный инфаркт миокарда (p<0,0001), наличие сахарного диабета (p<0,05) и ожирения (p<0,01). В многофакторном анализе, включающем, помимо коморбидных заболеваний, пол и возраст, статистическую значимость сохранил только перенесенный инфаркт миокарда в анамнезе (ОР смерти 1,009 (95%ДИ 1,004—1,014, p<0,001). ЗАКЛЮЧЕНИЕ У пациентов, перенесших ОНМК, отдаленную выживаемость ухудшало только наличие инфаркта миокарда в анамнезе.
- Open Access
- 29 November 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (10) , 3757
Two-year outcomes in patients after hospitalization for COVID-19: data from the TARGET-VIP registry
Aim. To evaluate 24-month outcomes after hospital treatment of patients with coronavirus disease 2019 (COVID-19) in a prospective registry.Material and methods. Two-year outcomes (2,2±0,5) after hospital treatment for COVID-19 were analyzed in 802 patients (mean age, 59,8±14,5 years, men, 51,0%). We assessed cases of death, non-fatal myocardial infarction (MI) and stroke, revascularization operations, hospitalizations, recurrent COVID-19, vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Results. During the follow-up period, 49 (5,9%) patients died, while 7 (0,8%) patients had MI, 7 (0,8%) — stroke. In addition, 222 (26,7%) patients were hospitalized, of which 26 (3,1%) for COVID-19. Recurrent COVID-19 were revealed in 146 (17,6%) patients, while 414 (49,6%) patients were vaccinated for SARS-CoV-2. The factors of age and stay in the intensive care unit were significantly associated (p2/3 during the first year. Factors associated with death were age, male sex, and intensive care unit treatment during the hospitalization. The readmission rate was associated with older age and CVDs. The risk of repeated cases of COVID-19 was one and a half times higher in the presence of CVDs, but 2 times lower in those vaccinated for SARS-CoV-2 in the post- COVID-19 period.
- 29 November 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (10) , 3757
Open AccessTwo-year outcomes in patients after hospitalization for COVID-19: data from the TARGET-VIP registry
Aim. To evaluate 24-month outcomes after hospital treatment of patients with coronavirus disease 2019 (COVID-19) in a prospective registry.Material and methods. Two-year outcomes (2,2±0,5) after hospital treatment for COVID-19 were analyzed in 802 patients (mean age, 59,8±14,5 years, men, 51,0%). We assessed cases of death, non-fatal myocardial infarction (MI) and stroke, revascularization operations, hospitalizations, recurrent COVID-19, vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Results. During the follow-up period, 49 (5,9%) patients died, while 7 (0,8%) patients had MI, 7 (0,8%) — stroke. In addition, 222 (26,7%) patients were hospitalized, of which 26 (3,1%) for COVID-19. Recurrent COVID-19 were revealed in 146 (17,6%) patients, while 414 (49,6%) patients were vaccinated for SARS-CoV-2. The factors of age and stay in the intensive care unit were significantly associated (p2/3 during the first year. Factors associated with death were age, male sex, and intensive care unit treatment during the hospitalization. The readmission rate was associated with older age and CVDs. The risk of repeated cases of COVID-19 was one and a half times higher in the presence of CVDs, but 2 times lower in those vaccinated for SARS-CoV-2 in the post- COVID-19 period.
- Open Access
- 23 September 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (8) , 5463
Medical follow-up and long-term survival of patients with cerebrovascular accident: data from the REGION-M registry
Aim. To assess the survival rate of patients after cerebrovascular accident (CVA), depending on the visits to the local outpatient clinic and the type of medical supervision, and in the first year after hospital discharge. Material and methods . The outpatient part of the REGION-M registry included 684 patients assigned to the City Polyclinic № 64 of Moscow, discharged from the F. I. Inozemtsev City Clinical Hospital (Moscow) in the period from January 1, 2012 to April 30, 2017 with a confirmed diagnosis of cerebral stroke/transient ischemic attack. Results. During the first year after the CVA, 451 (65,9%) patients visited the local clinic on their own (group 1), while 166 (24,3%) patients was consulted by house call (group 2), and 67 (9,8%) did not see the physician (group 3). Patients visited by house call were more likely to have prior coronary artery disease and stroke, and the age of men was older than in other groups. Patients who did not see a doctor were less likely to have comorbidities and disabilities, and were less likely to visit the clinic before stroke. The mortality of patients in group 3 was significantly higher throughout the entire follow-up period (55,2%, 70,1% and 77,6% at stages 1, 2 and 3 (pConclusion. The lower mortality among those visited the local clinic in the first year after CVA and among those who were visited by a doctor at home, compared with patients who were not observed, confirms the important role of medical supervision in the post-hospital period.
- 23 September 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (8) , 5463
Open AccessMedical follow-up and long-term survival of patients with cerebrovascular accident: data from the REGION-M registry
Aim. To assess the survival rate of patients after cerebrovascular accident (CVA), depending on the visits to the local outpatient clinic and the type of medical supervision, and in the first year after hospital discharge. Material and methods . The outpatient part of the REGION-M registry included 684 patients assigned to the City Polyclinic № 64 of Moscow, discharged from the F. I. Inozemtsev City Clinical Hospital (Moscow) in the period from January 1, 2012 to April 30, 2017 with a confirmed diagnosis of cerebral stroke/transient ischemic attack. Results. During the first year after the CVA, 451 (65,9%) patients visited the local clinic on their own (group 1), while 166 (24,3%) patients was consulted by house call (group 2), and 67 (9,8%) did not see the physician (group 3). Patients visited by house call were more likely to have prior coronary artery disease and stroke, and the age of men was older than in other groups. Patients who did not see a doctor were less likely to have comorbidities and disabilities, and were less likely to visit the clinic before stroke. The mortality of patients in group 3 was significantly higher throughout the entire follow-up period (55,2%, 70,1% and 77,6% at stages 1, 2 and 3 (pConclusion. The lower mortality among those visited the local clinic in the first year after CVA and among those who were visited by a doctor at home, compared with patients who were not observed, confirms the important role of medical supervision in the post-hospital period.